LINCS MCF 10A Common Project: Fixed-time-point sensitivity measures of the MCF 10A breast cell line to 8 small molecule perturbagens. Repeat performed by Scientist A in 2019 to assess reproducibility. Dataset 1 of 2: Normalized growth rate inhibition values. - Dataset - HMS LINCS Database

LINCS MCF 10A Common Project: Fixed-time-point sensitivity measures of the MCF 10A breast cell line to 8 small molecule perturbagens. Repeat performed by Scientist A in 2019 to assess reproducibility. Dataset 1 of 2: Normalized growth rate inhibition values. - Dataset (ID:20358)

Download: Excel (XLSX), Comma-separated (CSV)

Filter results: >>>>

|<
<<
Previous
Page 27 of 66
Next
>>
>
651 to 675 of 1647 records
per page:

Small Molecule	barcode	cell_count	frac_dead	corpse_count	cell_count_dead	row	column	agent	concentration	role	timepoint	replicate	cell_line	dead_count	fraction_dead	cell_count__time0	dead_count__time0	cell_count__ctrl	dead_count__ctrl	fraction_dead__ctrl	increase_fraction_dead	GRvalue
Dasatinib	180619_MC_10	12573	0.0190	54	186	12	4	Dasatinib	0.003326667	treatment	72	2	MCF10A-GM_3	240	0.0187	635.9	71.1	15071	356.7	0.0231	-0.00434	0.9222
Dasatinib	180619_MC_11	13758	0.0195	62	208	10	17	Dasatinib	0.003326667	treatment	72	2	MCF10A-GM_4	270	0.0192	635.9	71.1	15071	356.7	0.0231	-0.00383	0.9605
Dasatinib	180619_MC_11	12367	0.0235	80	212	10	18	Dasatinib	0.003326667	treatment	72	2	MCF10A-GM_5	292	0.0231	635.9	71.1	15071	356.7	0.0231	-0.00001	0.9152
Dasatinib	180619_MC_11	12198	0.0232	55	229	13	18	Dasatinib	0.003326667	treatment	72	2	MCF10A-GM_6	284	0.0228	635.9	71.1	15071	356.7	0.0231	-0.00032	0.9095
Dasatinib	180619_MC_12	13956	0.0246	82	264	6	19	Dasatinib	0.003326667	treatment	72	2	MCF10A-GM_7	346	0.0242	635.9	71.1	15071	356.7	0.0231	0.00112	0.9666
Dasatinib	180619_MC_12	13546	0.0340	177	290	9	3	Dasatinib	0.003326667	treatment	72	2	MCF10A-GM_8	467	0.0333	635.9	71.1	15071	356.7	0.0231	0.01025	0.9538
Dasatinib	180619_MC_12	14267	0.0214	97	210	11	19	Dasatinib	0.003326667	treatment	72	2	MCF10A-GM_9	307	0.0211	635.9	71.1	15071	356.7	0.0231	-0.00201	0.9761
Dasatinib	180619_MC_10	13173	0.0252	94	240	9	14	Dasatinib	0.00998	treatment	72	2	MCF10A-GM_1	334	0.0247	635.9	71.1	15071	356.7	0.0231	0.00165	0.9419
Dasatinib	180619_MC_10	10805	0.0192	49	159	12	9	Dasatinib	0.00998	treatment	72	2	MCF10A-GM_2	208	0.0189	635.9	71.1	15071	356.7	0.0231	-0.00419	0.8595
Dasatinib	180619_MC_10	11010	0.0291	76	247	13	3	Dasatinib	0.00998	treatment	72	2	MCF10A-GM_3	323	0.0285	635.9	71.1	15071	356.7	0.0231	0.00543	0.8671
Dasatinib	180619_MC_11	12136	0.0289	95	259	5	15	Dasatinib	0.00998	treatment	72	2	MCF10A-GM_4	354	0.0283	635.9	71.1	15071	356.7	0.0231	0.00527	0.9074
Dasatinib	180619_MC_11	12672	0.0232	69	226	8	20	Dasatinib	0.00998	treatment	72	2	MCF10A-GM_5	295	0.0228	635.9	71.1	15071	356.7	0.0231	-0.00032	0.9255
Dasatinib	180619_MC_11	12504	0.0257	88	235	9	15	Dasatinib	0.00998	treatment	72	2	MCF10A-GM_6	323	0.0252	635.9	71.1	15071	356.7	0.0231	0.00211	0.9199
Dasatinib	180619_MC_12	13307	0.0317	156	271	7	12	Dasatinib	0.00998	treatment	72	2	MCF10A-GM_7	427	0.0311	635.9	71.1	15071	356.7	0.0231	0.00802	0.9462
Dasatinib	180619_MC_12	13718	0.0250	150	197	9	10	Dasatinib	0.00998	treatment	72	2	MCF10A-GM_8	347	0.0247	635.9	71.1	15071	356.7	0.0231	0.00160	0.9592
Dasatinib	180619_MC_12	12939	0.0326	201	228	9	11	Dasatinib	0.00998	treatment	72	2	MCF10A-GM_9	429	0.0321	635.9	71.1	15071	356.7	0.0231	0.00902	0.9343
Dasatinib	180619_MC_10	10491	0.0249	83	180	8	21	Dasatinib	0.033266667	treatment	72	2	MCF10A-GM_1	263	0.0245	635.9	71.1	15071	356.7	0.0231	0.00138	0.8475
Dasatinib	180619_MC_10	10546	0.0273	45	244	11	16	Dasatinib	0.033266667	treatment	72	2	MCF10A-GM_2	289	0.0267	635.9	71.1	15071	356.7	0.0231	0.00360	0.8496
Dasatinib	180619_MC_10	10380	0.0256	47	220	12	18	Dasatinib	0.033266667	treatment	72	2	MCF10A-GM_3	267	0.0251	635.9	71.1	15071	356.7	0.0231	0.00200	0.8432
Dasatinib	180619_MC_11	10948	0.0331	78	287	3	7	Dasatinib	0.033266667	treatment	72	2	MCF10A-GM_4	365	0.0323	635.9	71.1	15071	356.7	0.0231	0.00919	0.8648
Dasatinib	180619_MC_11	12277	0.0229	73	210	6	15	Dasatinib	0.033266667	treatment	72	2	MCF10A-GM_5	283	0.0225	635.9	71.1	15071	356.7	0.0231	-0.00054	0.9122
Dasatinib	180619_MC_11	11513	0.0250	86	204	8	18	Dasatinib	0.033266667	treatment	72	2	MCF10A-GM_6	290	0.0246	635.9	71.1	15071	356.7	0.0231	0.00150	0.8855
Dasatinib	180619_MC_12	11621	0.0366	148	283	3	8	Dasatinib	0.033266667	treatment	72	2	MCF10A-GM_7	431	0.0358	635.9	71.1	15071	356.7	0.0231	0.01269	0.8893
Dasatinib	180619_MC_12	11832	0.0320	128	255	3	17	Dasatinib	0.033266667	treatment	72	2	MCF10A-GM_8	383	0.0314	635.9	71.1	15071	356.7	0.0231	0.00828	0.8968
Dasatinib	180619_MC_12	12937	0.0310	185	222	9	9	Dasatinib	0.033266667	treatment	72	2	MCF10A-GM_9	407	0.0305	635.9	71.1	15071	356.7	0.0231	0.00743	0.9342

|<
<<
Previous
Page 27 of 66
Next
>>
>
651 to 675 of 1647 records
per page:

HMS LINCS Project

LINCS MCF 10A Common Project: Fixed-time-point sensitivity measures of the MCF 10A breast cell line to 8 small molecule perturbagens. Repeat performed by Scientist A in 2019 to assess reproducibility. Dataset 1 of 2: Normalized growth rate inhibition values. - Dataset (ID:20358)